Discovery Pipeline

Apr 09, 2018
By BioPharm International Editors
National Institutes of Health researchers use genomics to show that squamous cell carcinomas differ from other cancers, which could advance treatments for head and neck and other cancers.
Mar 06, 2018
By BioPharm International Editors
The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.
Jan 11, 2018
By BioPharm International Editors
A Takeda and Denali collaboration includes three named programs for treating Alzheimer’s disease and other neurodegenerative diseases, using Denali’s antibody transport vehicle (ATV) technology to enhance blood-brain barrier penetration.
Jan 05, 2018
By BioPharm International Editors
The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.
Jan 05, 2018
By BioPharm International Editors
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
Aug 23, 2017
By BioPharm International Editors
AstraZeneca and Champions will develop new cohorts of patient-derived xenograft models to be used in oncology programs in breast and lung cancer as well as for use in other academic and industry applications.
May 08, 2017
Biomedical researcher shares insights from a career dedicated to advancing therapeutic innovations for unmet medical needs.
Mar 28, 2017
By BioPharm International Editors
The company has signed two separate agreements with the Agency for Science, Technology, and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
Mar 16, 2017
By BioPharm International Editors
Human antibody for Zika virus could help in the treatment and prevention of the infection.
Feb 14, 2017
Evaluate and BioPharm International highlight the antibody-based therapeutics that may have 2017 launch dates in the United States.
native1_300x100
lorem ipsum